Exelixis to Webcast Virtual Fireside Chat as Part of the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021
Exelixis, Inc. (Nasdaq: EXEL) announced that President and CEO Michael M. Morrissey, Ph.D., will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, at 1:00 PM EST. Due to the COVID-19 pandemic, the event will be virtual. Investors can access the webcast through the Exelixis website and are advised to join 15 minutes early. Exelixis is known for its oncology-focused biotechnology efforts, having developed four products and recognized for its rapid growth.
- None.
- None.
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer will participate in a fireside chat as part of the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26, 2021 at 1:00 PM EST / 10:00 AM PST. Due to the ongoing COVID-19 pandemic, the conference will be held as a virtual event.
To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune’s 100 Fastest-Growing Companies list for the first time, ranking 17th overall and the third-highest biopharmaceutical company. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a registered Japanese trademark.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210219005490/en/
FAQ
When will Michael M. Morrissey participate in the SVB Leerink 10th Annual Global Healthcare Conference?
How can I access the webcast for Michael M. Morrissey's presentation?
What is the main focus of Exelixis as a biotechnology company?
What products has Exelixis developed?
What recognition has Exelixis received in the past?
